‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer

Cancer News

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Back to Cancer Insights